DIA Biosimilars 2013

Avista Capital

Carlyle Partners, Hellman & Friedman to acquire PPD for $3.9 billion, take the CRO private

Monday, October 10, 2011 08:02 AM

It’s official: Large equity investors Carlyle Partners and Hellman & Friedman Capital Partners are buying publicly traded PPD, taking the CRO private.

More... »

Cenduit: Now with Patient Reminders

PRA on the block, too?

Monday, August 8, 2011 08:02 AM

There was much hoopla made about PPD possibly being for sale after the Wall Street Journal published a story saying as much in mid-July. But what about its smaller competitor, PRA International?

More... »

CRF Health – eCOA Forum

INC Research completes acquisition of Kendle International

Wednesday, July 13, 2011 10:31 AM

Raleigh, N.C.-based INC Research, a therapeutically focused CRO privately held by Avista Capital Partners and Ontario Teachers’ Pension Plan, has completed the acquisition of Kendle International in an all-cash transaction with a total equity value of approximately $232 million or $15.25 per share.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs